BAJAJ FINSERV DIRECT LIMITED
Open Your FREE Demat Account Now!

Supriya Lifescience Ltd. Share Price

NSE
BSE

NSE : SUPRIYA

BSE : 543434

Sector : Healthcare

N/A
indicator
1D
1M
3M
6M
1Y
5Y
empty graph

Day's Range

Day's Range

Low

₹675.80

High

₹700.55

Price Summary

Previous Close ₹683.85
Day's Range ₹675.80 - ₹700.55
Open ₹675.80
52 Week Range ₹545.50 - ₹832.40
Volume 83,486
Market Cap ₹0.01
Previous Close ₹684.10
Day's Range ₹671.10 - ₹700.20
Open ₹671.10
52 Week Range ₹545.65 - ₹831.00
Volume 6,975
Market Cap ₹0.01

Stocks Summary

Trade Value ( ₹ in Lacs) 570.92
Market Cap (₹ in Mn) 0.01
Dividend Yield(%) 0.15
Price/Earning (TTM) 29.38
TTM EPS (₹) 23.02
P/E Ratio 31.41
Book Value(₹) 4.81
PAT Margin (%) 24.04
Face Value (₹) 2.00
ROCE(%) 27.63
Trade Value ( ₹ in Lacs) 47.72
Market Cap (₹ in Mn) 0.01
Dividend Yield(%) 0.15
Price/Earning (TTM) 29.38
TTM EPS (₹) 23.02
P/E Ratio 31.41
Book Value(₹) 4.81
PAT Margin (%) 24.04
Face Value (₹) 2.00
ROCE(%) 27.63

Financials

Particulars QTR FY (₹ in Millions) Annual FY (₹ in Millions)
Net sales 1856.48 5703.4
Expenses N/A N/A
PBT 625.8 1656.9
Operating profit 0.0 0.0
Net profit 467.83 1191.14

Shareholding Pattern

Promoters (% Holding)

68.30%

Mutual funds (% Holding)

1.33%

Non-Institution (% Holding)

20.84%

FI/Banks/Insurance (% Holding)

2.35%

Government (% Holding)

0.00%

FII

5.16%

About Supriya Lifescience Ltd.

Founded 2008
Managing Director Saloni Satish Wagh
NSE Symbol SUPRIYA

Peer Comparision

Stocks Name Market Cap (Cr)(₹) Market Price (₹) 52 Week Low-High (₹)
Sun Pharmaceutical Industries Ltd. 4,42,893.24 1,824.40 1,548.00 - 1,548.00
Divi's Laboratories Ltd. 1,76,366.71 6,789.10 5,636.50 - 5,636.50
Torrent Pharmaceuticals Ltd. 1,48,240.79 4,325.20 3,102.00 - 3,102.00
Apollo Hospitals Enterprise Ltd. 1,15,309.54 8,008.45 6,696.50 - 6,696.50
Dr. Reddy's Laboratories Ltd. 1,06,009.78 1,265.10 1,148.40 - 1,148.40
Cipla Ltd. 1,04,365.52 1,330.35 1,165.70 - 1,165.70
Lupin Ltd. 1,02,690.68 2,215.45 1,836.80 - 1,836.80
Max Healthcare Institute Ltd. 99,183.27 1,025.35 903.00 - 903.00
Mankind Pharma Ltd. 98,147.87 2,415.30 1,909.70 - 1,909.70
Zydus Lifesciences Ltd. 93,655.23 940.00 835.50 - 835.50
no-content No Records Found

Latest News

Apr
22
2026
EQUITY Posted on Apr 22nd 2026

Supriya Lifescience informs about updates

Supriya Lifescience has informed that the US Food and Drug Administration (US FDA) conducted an inspection at the Company’s manufacturing facility located at Lote, Parshuram Industrial Area, Maharashtra, India, from 2 February 2026 to 6 February 2026. The inspection concluded with the issuance of a Form 483 containing one (1) minor observation. The Company has adequately addressed the observation and has received the Establishment Inspection Report (EIR) indicating ‘Voluntary Action Indicated (VAI)’, signifying a successful completion of the inspection. The Company remains committed to maintaining full compliance with current Good Manufacturing Practice (cGMP) requirements across all its manufacturing facilities.
The above information is a part of company’s filings submitted to BSE.
Read More
Feb
17
2026
EQUITY Posted on Feb 17th 2026

Supriya Lifescience informs about transcript of earnings Call

Further to its Letters dated February 04, 2026, February 09, 2026, and February 10, 2026, Supriya Lifescience has informed that the Transcript of the Earnings Call held on February 10, 2026, with respect to Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2025, is available on the Company's website at: https://www.supriyalifescience.com/ir-financial.php.

The above information is a part of company’s filings submitted to BSE.

Read More
May
13
2026
EQUITY Posted on May 13th 2026

Emmessar Biotech & Nutrition informs about press release

Emmessar Biotech & Nutrition has informed that it enclosed copies of Audited Financial Results of the Company for the quarter and financial year ended March 31, 2026 published in today’s newspapers in Free Press Journal and Nav Shakti in accordance with Regulation 47 of the Listing Regulations.
The above information is a part of company’s filings submitted to BSE.
Read More
May
13
2026
EQUITY Posted on May 13th 2026

Zydus Lifesciences informs about update on board meeting

Zydus Lifesciences has informed that this is in furtherance of earlier intimation dated May 8, 2026, about the meeting of the Board of Zydus Lifesciences (the Company) scheduled to be held on Tuesday, May 19, 2026. In terms of Regulation 29(1)(b) and Regulation 29(2) of the Listing Regulations, the Board of the Company, at its aforesaid meeting, will also consider the proposal for buyback of fully paid-up equity shares of the Company and the matters necessary and incidental thereto, in accordance with the applicable provisions under the Companies Act, 2013, as amended, (including the rules and regulations framed thereunder), the Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018, as amended, and other applicable laws. As intimated earlier, the trading window as per the SEBI (Prohibition of Insider Trading) Regulations, 2015 shall remain closed till Thursday, May 21, 2026, and shall open for trading on and from Friday, May 22, 2026, for all the Directors and Designated Persons of the Company. The trading window shall be deemed to be closed in respect of the aforementioned buyback proposal as well, in accordance with applicable laws.
The above information is a part of company’s filings submitted to BSE.
Read More
May
13
2026
EQUITY Posted on May 13th 2026

Indraprastha Medical Corporation informs about newspaper publication

Pursuant to Regulation 30 read with Schedule III (Part A) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Indraprastha Medical Corporation has submitted copies of the public notice of the financial results, published on 13th May, 2026, in the ‘Financial Express’, all India editions, in English language and in ‘Jansatta’, Delhi edition, in Hindi language.
The above information is a part of company’s filings submitted to BSE.
Read More
no-content No Records Found

Sign in to Unlock Offers!

Explore Loans, Cards, Investments & Insurance

No SPAM We don't SPAM
Right Hand Side Image
STEP 1/2

Open Demat Account today!

+91

Enter mobile number

Invalid mobile number

Enter Full Name

Invalid Full Name

Verification required
close

Enter the One Time Password (OTP)

Sent to ********99

Edit Number
Enter valid OTP
Field should not be blank
You have exhausted your OTP attempts try again after 10 min

Request another in 60s

Resend OTP

secure   100% safe and secure

Frequently Asked Questions

What is the current share price of Supriya Lifescience Ltd. ?

The current share price of Supriya Lifescience Ltd. is ₹683.85 as of 2026-05-13.

The market capitalisation of Supriya Lifescience Ltd. is ₹5,442.65 as of 2026-05-12.

The 1-year return of Supriya Lifescience Ltd. is 8.05% as of 2026-05-13.

The P/E ratio of Supriya Lifescience Ltd. is 31.41 as of 2026-05-13.

The 52-week high and low of Supriya Lifescience Ltd. are ₹832.40 and ₹545.50, respectively, as of 2026-05-13.

The dividend yield of Supriya Lifescience Ltd. is 0.1479% as of2026-05-12.

You can buy Supriya Lifescience Ltd. shares through a registered stockbroker or trading platform. Bajaj Markets partners with trusted brokers to help you open a demat account. This is the first step to trading, making it easier to invest in your desired shares.

The Managing Director of Supriya Lifescience Ltd. is Saloni Satish Wagh.

When investing in a company’s stock, you may consider key factors such as its fundamentals, including financial health, historical performance, and growth potential. Assess the consistency of its performance, market conditions, and industry trends. Additionally, evaluate your own risk tolerance while reviewing aspects like quarterly earnings, management quality, and sector performance, for taking a well-informed decision.

You can track stock performance on online platforms through live market updates, historical charts, and news alerts. Regular analysis and stock alerts allow you to stay informed about significant price changes and events affecting the stock.

Common stock provides voting rights and the potential for dividends based on company performance, while in case of preferred stock, stockholders receive fixed dividends and have priority over common stockholders in asset distribution but generally lack voting rights.

Stock investments carry market risks, including price volatility, economic shifts, and sector-specific issues. Managing risk can involve diversifying your portfolio, setting stop-loss orders, and staying informed about market trends to make timely decisions.

Market capitalisation, or market cap, is the total value of a company’s outstanding shares and is calculated by multiplying the stock price by the total shares. It classifies companies as large-cap, mid-cap, or small-cap, reflecting their size, stability, and potential risk level in the stock market.

View More

Disclaimer

This content is for educational purpose only and the same should not be construed as investment advice. Bajaj Finserv Direct Limited shall not be liable or responsible for any investment decision that you may take based on this content.

Disclaimer

All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.

The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.

Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform. 

Invalid Mobile Number

Invalid Full Name

Home
Home
ONDC_Shopping
Shopping
Loan
Loan Offers
My Accounts
My Accounts
Explore
Explore